From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA grants pediatric indication for 2 HCV drugs

from Pharmacy Practice News

The FDA approved new indications for sofosbuvir and ledipasvir-sofosbuvir to treat hepatitis C virus in children from 12 to 17 years of age. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. DAA drugs reduce the amount of HCV in the body by preventing the virus from multiplying, and in most cases, they cure HCV. These approvals provide pediatric treatment options for six major genotypes of HCV. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063